RTP Mobile Logo
Submitted by web@researchtop... on Wed, 05/29/2019 - 10:08

Interview with Emmanuel S Antonarakis, MD

Track 1: Initial evaluation of prognostic indicators in hormone-sensitive prostate cancer (HSPC) versus castration-resistant prostate cancer (CRPC)
Track 2: Effect of prostate-specific antigen (PSA) doubling time on time to metastasis and overall survival in nonmetastatic CRPC; improvement in metastasis-free survival with androgen receptor antagonist therapy
Track 3: Perspective on the use of intermittent androgen deprivation therapy (ADT) for patients with nonmetastatic HSPC and rising PSA levels
Track 4: Structural and mechanistic similarities and differences between available (apalutamide, enzalutamide) and investigational (darolutamide) androgen receptor antagonists
Track 5: Initial results of the Phase III ARAMIS trial: Metastasis-free survival improvement and tolerability of darolutamide versus placebo for nonmetastatic CRPC
Track 6: ARASENS: An ongoing Phase III trial evaluating darolutamide versus placebo in combination with standard ADT and docetaxel for patients with metastatic HSPC
Track 7: Perspective on the new drug application and potential FDA approval of darolutamide for nonmetastatic CRPC
Track 8: Spectrum and frequency of systemic and CNS-related side effects associated with apalutamide, enzalutamide and darolutamide
Track 9: Updated analysis of progression-free survival with first subsequent therapy (PFS2) in the SPARTAN study of apalutamide for high-risk nonmetastatic CRPC
Track 10: ARCHES: Design, efficacy and tolerability results from a Phase III trial of ADT with enzalutamide or placebo for metastatic HSPC
Track 11: Selection and sequencing of therapy for patients with metastatic prostate cancer
Track 12: Correlation between the presence of androgen receptor splice variant 7 (AR-V7) and outcomes with secondary hormonal therapy and chemotherapy in metastatic CRPC
Track 13: Prevalence and detection of AR-V7 in patients with metastatic CRPC
Track 14: Overview of BRCA1/2 and other DNA repair gene mutations that may confer sensitivity to PARP inhibition
Track 15: Efficacy and FDA breakthrough therapy designations for olaparib and rucaparib for metastatic CRPC
Track 16: GALAHAD: Preliminary results of a Phase II trial of niraparib for patients with metastatic CRPC and biallelic DNA repair gene defects
Track 17: Response to PARP inhibitor therapy in patients with metastatic CRPC with BRCA1/2 versus ATM mutations
Track 18: Activity of platinum-based chemotherapy in patients with metastatic CRPC and germline BRCA mutations
Track 19: Clinical experience with PARP inhibitor-associated side effects in men with metastatic CRPC
Track 20: Perspective on the negative results of the Phase III ERA 223 trial evaluating radium-223 dichloride in combination with abiraterone acetate for patients with chemotherapy-naïve metastatic CRPC and bone metastases
Track 21: Appropriate use of radium-223 for the treatment of symptomatic metastatic CRPC
Track 22: Biologic rationale for and ongoing investigation of lutetium-177-prostate-specific membrane antigen (PSMA)-617 for progressive PSMA-positive metastatic CRPC
Track 23: KEYNOTE-199: Updated analysis of a Phase II trial of pembrolizumab monotherapy for patients with metastatic CRPC previously treated with docetaxel
Track 24: Initial results of the Phase II CheckMate 650 trial of nivolumab with ipilimumab for metastatic CRPC
Track 25: Prevalence of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) molecular phenotype and response to immune checkpoint blockade in patients with prostate cancer
Track 26: Emerging data with olaparib in combination with anti-PD-1/PD-L1 checkpoint blockade for metastatic CRPC

Interview with Matthew R Smith, MD, PhD

Track 1: Recent advances in the treatment of nonmetastatic CRPC
Track 2: Effect of PSA doubling time on prognosis for patients with nonmetastatic disease
Track 3: PSA doubling time and clinical decision-making for patients with M0 disease
Track 4: Counseling patients with nonmetastatic disease about goals of therapy and expected side effects
Track 5: Similarities and differences in the design, entry criteria and efficacy endpoints among the ARAMIS, SPARTAN and PROSPER trials
Track 6: Comparison of the side-effect profiles of apalutamide, enzalutamide and darolutamide
Track 7: Counseling patients receiving long-term ADT about treatment-related fatigue
Track 8: Comparison of primary (metastasis-free survival) and secondary outcomes among the ARAMIS, SPARTAN and PROSPER trials
Track 9: Choosing among darolutamide, apalutamide and enzalutamide
Track 10: SPARTAN trial: PFS2 improvement with apalutamide for high-risk nonmetastatic CRPC
Track 11: Outcomes, tolerability and appropriate use of abiraterone in combination with prednisone
Track 12: Similarities and differences in the design, entry criteria and efficacy endpoints between the LATITUDE (ADT with abiraterone/prednisone or placebo) and ARCHES (ADT with enzalutamide or placebo) trials for patients with metastatic HSPC
Track 13: Key clinical and practical factors guiding the selection of docetaxel versus abiraterone/prednisone for metastatic HSPC
Track 14: Perspective on the intensification of therapy for patients with metastatic HSPC and suboptimal responses to ADT
Track 15: Spectrum and frequency of somatic and germline DNA repair gene mutations in prostate cancer; activity of PARP inhibitors in patients with metastatic CRPC
Track 16: Incidence of MSI-H/dMMR molecular phenotype in patients with prostate cancer; indications for testing and current role of immune checkpoint inhibitors
Track 17: Results of a Phase II prospective trial of lutetium-177-PSMA-617 theranostics in metastatic CRPC
Track 18: Novel immune checkpoint inhibitor-based combinations for metastatic CRPC
 
FACULTY:
 
Emmanuel S Antonarakis, MD
Associate Professor of
Oncology and Urology
Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center
Baltimore, Maryland
 
Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed
Chair in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director
Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
 
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida